F
The startup is developing an oral compound that targets leukemic stem cells by inhibiting a master switch associated with refractory acute myeloid leukaemia (AML). This approach aims to prevent relapse in patients who have undergone treatment for AML, addressing a critical gap in current cancer therapies.
San Francisco, United States
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup is developing an oral compound that targets leukemic stem cells by inhibiting a master switch associated with refractory acute myeloid leukaemia (AML). This approach aims to prevent relapse in patients who have undergone treatment for AML, addressing a critical gap in current cancer therapies.